Key strategies to address Covid-19 related clinical trial disruptions by geography

3 March 2021 (Last Updated March 3rd, 2021 10:23)

Pharmaceutical companies have started exploring new strategies to address growing disruptions in conducting clinical trials amid Covid-19 pandemic.

Pharmaceutical companies have started exploring new strategies to address growing disruptions in conducting clinical trials amid Covid-19 pandemic.

GlobalData conducted a survey to identify the key strategies that the companies in North America, Europe, Asia Pacific and Rest of World (RoW) are adopting to tackle clinical trial disruptions due to the outbreak.

Key strategies to address Covid-19 related clinical trial disruptions by geographyAddressing Clinical Trial Disruptions Related to the Covid-19 Outbreak by Geography

An assessment of the survey results shows that majority of the companies are resorting to remote patient monitoring (RPM) and decentralised trials to mitigate the impact of Covid-19 pandemic.

Around 18% of the respondents in North America are turning to RPM to monitor clinical trial patients over phone, email or patient portal. It is 16% in Europe, 15% in Asia-Pacific and 12% in RoW.

The respondents from RoW region (18%) leads in planning to move to decentralised/ virtual clinical trials in future, followed by North America (16%), Asia Pacific (15%) and Europe (14%).

Approximately 15% of the respondents each in North America and Asia Pacific regions are exploring remote site initiation visits for critical trials. It is 12% and 11% in RoW and Europe, respectively.

Around 16% of the companies in Asia Pacific have mandated research staff to work remotely to address trial disruptions. It is 13%, 13% and 10% for North America, Europe and RoW, respectively.

In North America and RoW, around 13% and 12% of the respondents are planning to switch to direct-to-patient (DTP) drug delivery. Only 11% of the companies in Europe and 7% in Asia Pacific are exploring the same.

A total of 12% of the respondents in RoW, 11% in Europe, 10% in Asia Pacific and 8% in North America have halted screening or enrolment for all clinical trials.

The RoW (10%) tops in prioritising enrolment for certain clinical trials, followed by Asia Pacific (9%), North America (7%) and Europe (5%).

In the survey, around 9% of the companies each in Asia Pacific and Europe said that they have implemented remote safety lab collections. Approximately 8% respondents in RoW and 5% in North America expressed similar strategies.

Europe (9%) leads in ceasing opening of any new clinical trials, followed by RoW (8%), North America (6%) and Asia Pacific (4%) regions.

The analysis is based on responses received for the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.